Pandion

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Buyout Investigation

Retrieved on: 
Thursday, March 4, 2021
Bayer, Kenilworth, New Jersey, Merck & Co., Schering-Plough, Fiduciary, Pandion, NASDAQ, Companies, Economy of the United States, New York City

announces that it is investigating:

Key Points: 
  • announces that it is investigating:
    Pandion Therapeutics, Inc. (NASDAQ GS: PAND ) regarding possible breaches of fiduciary duties and other violations of law related to Pandions agreement to be acquired by Merck & Co., Inc.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pandion-therapeutics-inc .
  • Under the terms of the agreement, PRA Healths shareholders will receive 0.4125 shares of ICON and $80.00 in cash per share.
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

Merck Begins Tender Offer to Acquire Pandion Therapeutics

Retrieved on: 
Thursday, March 4, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Corporate finance, Tender offer, SEC filings, Schedule TO, Pandion, Offer

Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes.

Key Points: 
  • Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes.
  • Following the purchase of shares in the tender offer, Pandion will become a subsidiary of Merck.
  • Merck will file today with the U.S. Securities and Exchange Commission (the SEC) a tender offer statement on Schedule TO, which provides the terms of the tender offer.
  • Additionally, Pandion will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of the Pandion board of directors that their stockholders accept the tender offer and tender their shares.

Penn Power Partners with Erie Bird Observatory for Second Consecutive Year to Protect Nesting Birds, Prevent Power Outages

Retrieved on: 
Wednesday, March 3, 2021
Electric power, Osprey, Pandion, Utility pole, FirstEnergy, Energy, Infrastructure

This proactive work will discourage ospreys from nesting on utility poles when they return to the area in the coming weeks.

Key Points: 
  • This proactive work will discourage ospreys from nesting on utility poles when they return to the area in the coming weeks.
  • Over the past two years, the FirstEnergy Foundation has donated a total of $10,000 to the Erie Bird Observatory to fund the construction of nesting platforms across western Pennsylvania.
  • In recent years, Penn Power has worked with the organization to install seven nesting platforms adjacent to utility poles that have experienced high levels of osprey activity.
  • These nesting habits often place the birds near energized electrical equipment jeopardizing their well-being and potentially causing power outages.

PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND

Retrieved on: 
Tuesday, March 2, 2021
Legal, Professional services, Foti, Pandion, MRK

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Pandion Therapeutics, Inc. (NasdaqGS: PAND) to Merck (NYSE: MRK).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Pandion Therapeutics, Inc. (NasdaqGS: PAND) to Merck (NYSE: MRK).
  • Under the terms of the proposed transaction, shareholders of Pandion will receive only $60.00 in cash for each share of Pandion that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout

Retrieved on: 
Thursday, February 25, 2021
Pandion, Merck & Co., MRK, Fiduciary, Merck, NASDAQ, New York Stock Exchange, Companies, New York City, Economy of the United States

announces that it is investigating Pandion Therapeutics, Inc. (Pandion) (NASDAQ GS: PAND ) regarding possible breaches of fiduciary duties and other violations of law related to Forterras agreement to be acquired by Merck & Co., Inc. (Merck) (NYSE: MRK ).

Key Points: 
  • announces that it is investigating Pandion Therapeutics, Inc. (Pandion) (NASDAQ GS: PAND ) regarding possible breaches of fiduciary duties and other violations of law related to Forterras agreement to be acquired by Merck & Co., Inc. (Merck) (NYSE: MRK ).
  • Under the terms of the agreement, Pandions shareholders will receive $60.00 in cash per share.
  • To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pandion-inc .
  • You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] .

PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 25, 2021
Corporate finance, Stock market, Finance, Money, Corporations, Security, Pandion, Derivative, Stock, Mergers and acquisitions

On February 25, 2021, Pandion announced that it had signed an agreement to be acquired by Merck for approximately $1.85 billion.

Key Points: 
  • On February 25, 2021, Pandion announced that it had signed an agreement to be acquired by Merck for approximately $1.85 billion.
  • Pursuant to the merger agreement, Pandion stockholders will receive $60 in cash for each share of Pandion common stock owned.
  • Bragar Eagel & Squire is concerned that Pandions board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Pandion Therapeutics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Pandion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PAND

Retrieved on: 
Thursday, February 25, 2021
Legal, Professional services, Articles, Legal entities, Pandion, Limited liability partnership, Securities fraud, Shareholder, Business, Organizations

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders.

Key Points: 
  • Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. (NASDAQ: PAND) to Merck is fair to Pandion shareholders.
  • Under the terms of the agreement, Pandion shareholders will receive $60.00 per share in cash.
  • On behalf of Pandion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Pandion Emerges from Stealth with $4.9 Million for More Reliable, Lower Cost E-commerce Shipping

Retrieved on: 
Tuesday, February 2, 2021
Technology, Logistics, Supply chain management, Transport, Other Technology, Software, Networks, Internet, Parcel, Freight transport, Transport, Economy, Supply chain management, Pandion, Playground Global, Schematic Ventures

Pandion will use the proceeds from this round to grow the team and expand ongoing customer pilots.

Key Points: 
  • Pandion will use the proceeds from this round to grow the team and expand ongoing customer pilots.
  • E-commerce currently relies on outdated parcel providers that lack the ability to scale their capacity up or down as needed.
  • The annual holiday shipping crunch illustrates how easily strained these legacy providers are when parcel volume increases.
  • We are building the modern small parcel provider tuned specifically to provide low cost, high performance delivery that e-commerce needs.

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

Retrieved on: 
Thursday, December 3, 2020
Pandion

Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for companies in the life sciences industry.

Key Points: 
  • Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for companies in the life sciences industry.
  • We look forward to her contributions to the growth and value creation for Pandion as a newly public company, said Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics.
  • Ms. Dorton currently serves on the board of directors for Fulcrum Therapeutics (Nasdaq: FULC) and US Ecology (Nasdaq: ECOL).
  • Pandion Therapeuticsis developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.

Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit

Retrieved on: 
Thursday, September 24, 2020
Autoimmune disease, RTT, Pandion, Draft:Pandion Therapeutics

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m.

Key Points: 
  • WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m.
  • A live audio webcast of the panel will be available on the Investors and News section of Pandion Therapeutics investor website at https://investors.pandiontx.com/ .
  • Pandion Therapeuticsis developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.
  • Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline.